Evidence map›Paper›PMID 41001377›Full record

ReviewFrontiers in medicine2025

Biomarker research for Henoch-Schönlein purpura nephritis based on "omics" techniques.

Xuejiao Zhou, Zhengwei Yuan, Hongkun Jiang, Yaoyao Ju, Cheng Chen, Wenjie Zhang, Huining Liu, Liqing Zhang, Meixia Qi, Dong An

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xuejiao ZhouDepartment of Pediatrics, The First Affiliated Hospital of China Medical University, Shenyang, China.
Zhengwei YuanKey Laboratory of Health Ministry for Congenital Malformation, Shengjing Hospital, China Medical University, Shenyang, China.
Hongkun JiangDepartment of Pediatrics, The First Affiliated Hospital of China Medical University, Shenyang, China.
Yaoyao JuDepartment of Pediatrics, The First Affiliated Hospital of China Medical University, Shenyang, China.
Cheng ChenDepartment of Pediatrics, The First Affiliated Hospital of China Medical University, Shenyang, China.
Wenjie ZhangDepartment of Pediatrics, The First Affiliated Hospital of China Medical University, Shenyang, China.
Huining LiuDepartment of Pediatrics, The First Affiliated Hospital of China Medical University, Shenyang, China.
Liqing ZhangDepartment of Pediatrics, The Fifth People's Hospital of Datong, Datong, China.
Meixia QiDepartment of Pediatrics, The Fifth People's Hospital of Datong, Datong, China.
Dong AnDepartment of Pediatrics, The First Affiliated Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Henoch-Schönlein purpura (HSP) is a common autoimmune disease in children. The lesions primarily involve small vessels in the skin, kidneys, joints and intestines. Henoch-Schönlein purpura nephritis (HSPN) caused by HSP is the main factor affecting the prognosis and outcome of the disease, and severe cases may develop into end-stage renal insufficiency. Renal biopsy serves as the primary diagnostic tool for HSPN, but it is an invasive test with poor reproducibility. Which is not conducive to clinical promotion. The discovery of new biomarkers using traditional laboratory testing methods and omics techniques provide new possibilities for HSPN to discover additional biomarkers, such as genomics, transcriptomics, proteomics, metabolomics and epigenomics. These technologies offer benefits such as high throughput, high sensitivity, and reduced need for biological fluid samples, which are expected to make greater contributions to the screening of promising biomarkers for purpuric nephritis. The current article reviews recent advances in omics-based research on potential biomarkers in samples from different sources of HSPN, including blood, urine, kidney tissue, and associated cells, which may provide a foundation for early diagnosis, prognosis, and treatment of HSPN.

Indexed as

biomarkerHenoch-Schönlein purpuraHenoch-Schönlein purpura nephritisimmunoglobulin A vasculitisomics

Identifiers

PMID41001377
PMCPMC12457392

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.